Targeting Muco-Obstructive Lesions to Redefine COPD Treatment
- Mucus plugs represent the last untargeted cause of airway obstruction in COPD, persisting even in patients escalated to triple therapy or biologics
- MLT-001 by MucoLife Therapeutics is a first-in-class inhaled mucus modulator with a novel mechanism of action that directly dissolves mucus plugs with demonstrated 90% preclinical efficacy and a wide therapeutic index
- The talk will highlight the addressable COPD subgroup and how MLT-001 is positioned as a once-daily inhaled add-on maintenance therapy within the existing treatment paradigm. Additionally, the presentation will explore the broader platform potential of this mechanism across other muco-obstructive diseases, including non-CF bronchiectasis, asthma